Biogen Inc. (Biogen) expects that its GAAP and non-GAAP results for the second quarter of 2026 will include acquired in-process research and development, upfront and milestone expense of approximately $164 million on a pre-tax basis. The estimated charge is expected to impact GAAP and non-GAAP net income per diluted share for the second quarter of 2026 by approximately $0.95 per share.

Additionally, Biogen anticipates its GAAP and non-GAAP results for the third quarter of 2026 to include acquired in-process research and development, upfront and milestone expense ranging from approximately $290 million to $320 million relating to potential milestones and transactions that have not yet closed. The estimated charge is anticipated to impact GAAP and non-GAAP net income per diluted share for the third quarter of 2026 ranging from approximately $1.75 to $1.95 per share.